BioSpace News Archive

UCB, a global biopharmaceutical company, announced that it will present six abstracts in hidradenitis suppurativa at the 8th Annual Symposium on Hidradenitis Suppurativa Advances, October 13–15 in Phoenix, Arizona.

Flare Therapeutics today announced a new study describing a robust artificial intelligence (AI)-based model in partnership with PathAI that accurately predicts luminal muscle invasive urothelial cancer (MIUC), characterized by high peroxisome proliferator-activated receptor gamma (PPARG) expression using H&E-stained slides.

Illumina, Inc., has received an order from the European Commission directing the company to divest GRAIL.

AquaBounty Technologies, Inc. (NASDAQ: AQB) (“AquaBounty” or the “Company”), a land-based aquaculture company utilizing technology to enhance productivity and sustainability

Palatin Technologies, Inc. announced it received a notice from the staff of NYSE American LLC that Palatin was not in compliance with the Exchange’s continued listing standards under Section 1003 and of the NYSE American Company Guide.

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that the Company will present 11 abstracts, including two late-breaking oral presentations, at the upcoming American Society of Nephrology (ASN) Kidney Week 2023 in Philadelphia, PA, November 2-5, 2023.

Leading health and well-being company Humana Inc. announced that, for the third consecutive year and the fourth time overall, its statewide Humana HMO Medicare Advantage plan in Tennessee has achieved the highest possible 5-star rating from the Centers for Medicare & Medicaid Services.

VolitionRx Limited, a multi-national epigenetics company, has published a report summarising key themes from its recent Key Opinion Leader roundtable on sepsis management.

SOTIO Biotech, a clinical-stage immuno-oncology company owned by PPF Group, today announced it will discontinue the currently ongoing clinical trials of nanrilkefusp alfa as monotherapy and in combinations with pembrolizumab and cetuximab.

FOXO Technologies Inc. announced that the United States Patent & Trademark Office has provided an Issue Notification for a key patent utilizing a machine learning model trained to determine a biochemical state and/or medical condition using DNA epigenetic data to enable the commercialization of epigenetic biomarkers.